Specifica Reaches Antibody Discovery Platform Transfer Agreement with Sanofi
Specifica Reaches Antibody Discovery Platform Transfer Agreement with Sanofi
Specifica, a privately held biotechnology company specializing in innovative in vitro antibody discovery technologies, has entered into an antibody discovery platform transfer agreement with Sanofi, one of the world’s leading healthcare companies.
Under the terms of the agreement, Specifica will transfer its Generation 3 (Gen 3) Antibody Discovery Platform to Sanofi, enabling the global biopharmaceutical company to integrate the technology into its antibody discovery and therapeutic development programs. The agreement represents an important milestone for Specifica and highlights the growing industry interest in advanced antibody engineering technologies designed to accelerate the development of next-generation medicines.
Antibody-based therapies have become an increasingly important component of modern medicine, providing treatments for a wide range of diseases, including cancer, autoimmune disorders, infectious diseases, and other serious health conditions. The discovery of high-quality therapeutic antibodies is a critical step in the drug development process, and technologies that improve the efficiency and success of antibody discovery can significantly impact the development of new treatments.
Specifica’s Gen 3 Antibody Discovery Platform was developed to address many of the challenges associated with identifying and optimizing therapeutic antibody candidates. The platform combines clinically validated antibody frameworks with compatible binding loop sequences derived from natural human antibodies. These sequences have been carefully selected and engineered to remove sequence-based developability liabilities that can negatively affect therapeutic performance, manufacturing, or stability.
By incorporating these optimized libraries into the discovery process, researchers can identify antibody candidates with strong binding properties while simultaneously improving characteristics important for drug development. This approach has the potential to streamline the path from discovery to clinical development and increase the likelihood of generating successful therapeutic candidates.
According to Specifica CEO Ken Sharples, the partnership with Sanofi provides access to a comprehensive antibody discovery solution. He noted that the collaboration combines Gen 3 libraries, antibody optimization technologies, and integrated discovery tools to create a complete platform for antibody discovery and development.
The agreement underscores the value of Specifica’s technology and reflects the continued demand for innovative approaches that can enhance the speed, quality, and efficiency of therapeutic antibody discovery. By integrating the Gen 3 platform into its research programs, Sanofi will further strengthen its capabilities in identifying and developing novel antibody-based therapies for patients worldwide.
As the biopharmaceutical industry continues to pursue more targeted and effective treatments, partnerships such as this one demonstrate the important role that advanced discovery platforms play in supporting the next generation of therapeutic innovation.
Specifica is a start up company in New Mexico that was originally supported by the New Mexico Consortium.
Read more on Specifica’s News Page.